These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21200020)
21. [Correlations Between Wang XM; Ye YX; Yang L; Lu XJ; Ying BW Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):931-935. PubMed ID: 28598127 [TBL] [Abstract][Full Text] [Related]
22. Definition of a small core transcriptional circuit regulated by AML1-ETO. Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982 [TBL] [Abstract][Full Text] [Related]
23. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs. Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970 [TBL] [Abstract][Full Text] [Related]
24. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439 [TBL] [Abstract][Full Text] [Related]
25. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037 [TBL] [Abstract][Full Text] [Related]
26. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523 [TBL] [Abstract][Full Text] [Related]
27. RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs. Gerritsen M; Yi G; Tijchon E; Kuster J; Schuringa JJ; Martens JHA; Vellenga E Blood Adv; 2019 Feb; 3(3):320-332. PubMed ID: 30709863 [TBL] [Abstract][Full Text] [Related]
29. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation. Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627 [TBL] [Abstract][Full Text] [Related]
30. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia. Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243 [TBL] [Abstract][Full Text] [Related]
31. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells. Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288 [TBL] [Abstract][Full Text] [Related]
34. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Yuan Y; Zhou L; Miyamoto T; Iwasaki H; Harakawa N; Hetherington CJ; Burel SA; Lagasse E; Weissman IL; Akashi K; Zhang DE Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10398-403. PubMed ID: 11526243 [TBL] [Abstract][Full Text] [Related]
35. TAF1 plays a critical role in AML1-ETO driven leukemogenesis. Xu Y; Man N; Karl D; Martinez C; Liu F; Sun J; Martinez CJ; Martin GM; Beckedorff F; Lai F; Yue J; Roisman A; Greenblatt S; Duffort S; Wang L; Sun X; Figueroa M; Shiekhattar R; Nimer S Nat Commun; 2019 Oct; 10(1):4925. PubMed ID: 31664040 [TBL] [Abstract][Full Text] [Related]
36. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158 [TBL] [Abstract][Full Text] [Related]
37. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Wang L; Gural A; Sun XJ; Zhao X; Perna F; Huang G; Hatlen MA; Vu L; Liu F; Xu H; Asai T; Xu H; Deblasio T; Menendez S; Voza F; Jiang Y; Cole PA; Zhang J; Melnick A; Roeder RG; Nimer SD Science; 2011 Aug; 333(6043):765-9. PubMed ID: 21764752 [TBL] [Abstract][Full Text] [Related]
38. AML1/ETO accelerates cell migration and impairs cell-to-cell adhesion and homing of hematopoietic stem/progenitor cells. Saia M; Termanini A; Rizzi N; Mazza M; Barbieri E; Valli D; Ciana P; Gruszka AM; Alcalay M Sci Rep; 2016 Oct; 6():34957. PubMed ID: 27713544 [TBL] [Abstract][Full Text] [Related]